Press Releases

ImQuest BioSciences Named 2017 Frederick County Best Place to Work

Frederick, MD August 2nd, 2017 -- On July 27th, ImQuest BioSciences was announced as the winner of the 2017 Frederick County Best Places to Work, in the Medium Business Category. The best places to work campaign recognizes the county’s most innovative, creative, and forward-thinking employers in Frederick, County Maryland. "Frederick County is a great place […]

August 3, 2017 | Read More

ImQuest BioSciences Expands In Vitro Toxicology Testing Services

ImQuest BioSciences now offers validated assays to determine the toxic effects of small molecules and biologics on mitochondrial function, and are offered as a component of ImQuest's mechanism of toxicity assays.

March 6, 2017 | Read More

ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women

ImQuest Pharmaceuticals was recently notified by the US Food and Drug Administration of the approval of its Investigational New Drug (IND) application to study the safety in Phase 1 clinical trials of its vaginal gel containing the nonnucleoside reverse transcriptase HIV Inhibitor IQP-0528.

July 16, 2014 | Read More

ImQuest BioSciences Celebrates 10 Year Anniversary, Launches ImQuestSUCCESS, Expedited Drug Discovery and Development Platform

ImQuest BioSciences, a leading pre-clinical contract research and development company that evaluates the potential of new and novel pharmaceutical products, today announced the launch of its ImQuestSUCCESS platform in conjunction with the celebration of its 10 year anniversary.

June 10, 2014 | Read More

Neutropenic Mouse Thigh Model Now Offered by ImQuest BioSciences

ImQuest BioSciences (Frederick, MD), in collaboration with Noble Life Sciences (Gaithersburg, MD), has successfully developed a neutropenic mouse thigh model of infection and demonstrated its use in a study evaluating vancomycin for the treatment of Staphylococcus aureus infection.

October 7, 2013 | Read More

ImQuest BioSciences Taps Warschawski to Create New Website and Collateral Materials

Warschawski announced today that ImQuest BioSciences, Inc., has hired them to create a new website and collateral materials for the company. Warschawski recently worked with ImQuest BioSciences, a provider of pre-clinical research and drug development services, to clarify its brand DNA and brand strategy. Based on the success of this collaboration, Warschawski has been retained to create new marketing materials that represent the new ImQuest BioSciences brand.

September 23, 2013 | Read More

Warschawski Hired by ImQuest BioSciences Inc., Provider of Pre-clinical Research and Drug Development Services

Warschawski announced today the addition of a new account to its agency roster. The pre-clinical research and drug development services company, ImQuest BioSciences Inc., will work with Warschawski on brand research, key messaging and brand positioning. Terms of the agreement were not disclosed.

April 15, 2013 | Read More

ImQuest Receives $14.2 Million Five-Year Grant from NIH to Develop a Dual Compartment Topical Microbicide To Prevent HIV Transmission

ImQuest BioSciences, Inc. announced today the successful acquisition of funding from the National Institutes of Health to support the development of a safe and effective microbicide product that will be designed for both vaginal and rectal use.

August 1, 2012 | Read More

ICAR Presentation: IND-Directed Development of Dual-Acting Pyrimidinediones IQP-0410 and IQP-0528: Enhancement of Solubility and Metabolic Stability

A poster entitled "IND-Directed Development of Dual-Acting Pyrimidinediones IQP-0410 and IQP-0528: Enhancement of Solubility and Metabolic Stability" was presented at the 2012 International Conference for Antiviral Research (ICAR) in Sapporo, Japan.

April 10, 2012 | Read More

ICAR Presentation: "Critical Role of a Serum Factor in Facilitating Efficient Synthesis of Hepadnaviral cccDNA"

Dr. Robert Buckheit was recently invited to give an oral presentation about critical role of a serum factor in facilitating efficient synthesis of hepadnaviral cccDNA in 2012 International Conference on Antiviral Research held in Sapporo, Japan, April 16-19.

April 8, 2012 | Read More

ICAR Presentation: "Muti-Pathway Development of Dual-Acting Pyrimidinedione NNRTIs as HIV Topical Microbicides"

Dr. Robert W. Buckheit Jr., President and CEO presented an oral presentation entitled “Muti-Pathway Development of Dual-Acting Pyrimidinedione NNRTIs as HIV Topical Microbicides” as part of the 25th International Conference on Antiviral Research in Sapporo, Japan.

April 7, 2012 | Read More

Microbicides Presentation: “User Experience Shapes Meaning Making & the Acceptability of Intravaginal Rings and Long-Acting Vaginal Gels”

Ms. Karen Buckheit presented an oral presentation entitled “User Experience Shapes Meaning Making & the Acceptability of Intravaginal Rings and Long-Acting Vaginal Gels” as part of the International Microbicides Conference in Sydney, Australia.

April 5, 2012 | Read More

Microbicides Presentations: “Development of a Combination Microbicide Gel Formulation Containing IQP-0528 and Tenofovir for the Prevention of HIV Infection”

At the Microbicides 2012 meeting held in Sydney, Australia, ImQuest BioSciences presented the results of two projects in formulation development for novel microbicides.

April 1, 2012 | Read More

Review Manuscript: An Algorithm for the Preclinical Development of Anti-HIV Topical Microbicides

Dr. Robert W. Buckheit Jr., President and CEO and Karen W. Buckheit, Director of Topical Microbicide and STI Research have published a review article on entitled “An Algorithm for the Preclinical Development of Anti-HIV Topical Microbicides” in Current HIV Research (PMID:22264051, January 13, 2012).

January 13, 2012 | Read More

Publication in Antimicrobial Agents and Chemotherapy: Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides

Karen W. Buckheit, Director of Topical Microbicide Development and STI Research has published a manuscript with co-authors Dr. Robert W. Buckheit Jr. and Dr. Lu Yang entitled “Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides” which was published in Antimicrobial Agents and Chemotherapy (2011, 55(11), 5243-5254, PMCID: 3195032).

November 1, 2011 | Read More

Publication in Antiviral Research: PYDs in Combination with Approved Anti-HIV Drugs

Tracy Hartman, Director of Anti-Infective Research, has published a manuscript with co-authors Dr. Robert W. Buckheit Jr. and Dr. Lu Yang entitled “Antiviral Interactions of Combinations of Highly Potent 2,4(1H,3H)-pyrimidinedione congeners and Other Anti-HIV Agents” which was published in Antiviral Research (2011, 92, p.505-508).

October 10, 2011 | Read More

National AAPS Presentation: Transdermal Films for the Delivery of HIV Therapeutics

In 2010, Dr. Ham was awarded a Phase I SBIR grant to develop transdermal films for the delivery of HIV therapeutics.

October 1, 2011 | Read More

ICAR Presentation/MIP V Grant: Development of Antimicrobial Peptides as Topical Microbicides for the Prevention of HIV

Karen Watson, Director of Topical Microbicide and STI Research, presented a poster entitled “Development of Antimicrobial Peptides as Topical Microbicides for the Prevention of HIV” at the 2011 International Conference for Antiviral Research (ICAR) in Sofia, Bulgaria.

May 1, 2011 | Read More

ICAR Presentation: In Vitro Cytoprotection Assay for Identifying Inhibitors of Xenotropic Murine Leukemia-Related Virus

Tracy Hartman, Director of Anti-Infective Research, presented a poster entitled "In Vitro Cytoprotection Assay for Identifying Inhibitors of Xenotropic Murine Leukemia-Related Virus" at the 2011 International Conference for Antiviral Research (ICAR) in Sofia, Bulgaria.

| Read More

New Hire: Dr. Mansoora Khaliq had joined ImQuest to lead our Microbiology and dengue virus program

Dr. Mansoora Khaliq had joined ImQuest to lead our Microbiology and dengue virus program.

February 1, 2011 | Read More

DART Presentation: Development of Next Generation Pyrimidinedione Inhibitors of HIV

Tracy Hartman, Director of Anti-Infective Research, presented a poster entitled "Development of Next Generation Pyrimidinedione Inhibitors of HIV" at the 2010 Frontiers in Drug Development and Antiretroviral Therapies (DART) in Cabo San Lucas, Mexico.

December 10, 2010 | Read More

DART Presentation/Poster Award: Development of IQP-0528 in a Combination Gel with Tenofovir

Karen Watson, Director of Topical Microbicide and STI Research, presented a poster entitled "Development of IQP-0528 in a Combination Gel with Tenofovir" at the 2010 Frontiers in Drug Development and Antiretroviral Therapies (DART) in Cabo San Lucas, Mexico.

December 1, 2010 | Read More

Microbicides Presentation: Vaginal Film Drug Delivery of the Pyrimidinedione IQP 0528 for the Prevention of HIV Infection

Dr. Ham was awarded a multi-year Microbicides Innovation Program grant to develop a novel nanoparticle pyrimidinedione formulation delivered via a quick dissolving vaginal film.

February 1, 2010 | Read More

ImQuest BioSciences Has Hired Dr. Anthony Ham Ph.D. to Lead Formulation Research and Development

ImQuest BioSciences has hired Dr. Anthony Ham Ph.D. to lead formulation research and development.

February 1, 2009 | Read More